Anti-Misuse Microparticulate Oral Drug Form

• US 20090041838A1
• Filed: 02/08/2006
• Published: 02/12/2009
• Est. Priority Date: 02/08/2005
• Status: Abandoned Application

• Current Assignee: Flamel Technologies SA (Avadel Pharmaceuticals Plc)
• Original Assignee: Flamel Technologies SA (Avadel Pharmaceuticals Plc)
• Inventors: Guimberteau, Florence, Soula, Gerard, Meyrueix, Remi
• Application Number:
  US11/883,935
• Publication Number:
  US 20090041838A1
• Time in Patent Office: Days
• US Class Current: 424/452
• CPC Class Codes: A61K 31/196 the amino group being directly attached to a ring, e.g. anthranilic acid, mefenamic acid, diclofenac, chlorambucil
• CPC Class Codes: A61K 31/522 having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
• CPC Class Codes: A61K 9/5047 Cellulose ethers containing no ester groups, e.g. hydroxypropyl methylcellulose
• CPC Class Codes: A61K 9/5078 with drug-free core
• CPC Class Codes: A61P 25/04 Centrally acting analgesics, e.g. opioids
• CPC Class Codes: A61P 29/00 Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
• CPC Class Codes: A61P 31/12 Antivirals

Abstract

The invention relates to solid microparticulate oral dosage forms having a composition that prevents the misuse of the active pharmaceutical ingredient (API) contained therein. The aim of the invention is to prevent the improper use of solid oral drugs for any use other than the therapeutic use(s) officially approved by the appropriate public health authorities. Another aim of the invention is to provide novel analgesic drugs which can be used to: prevent the misuse of, and addiction to certain analgesics and/or to control plasma concentration variability and/or to facilitate oral; administration; and/or to combine analgesics with one another and/or with one or more active ingredients in the same oral form. More specifically, the invention relates to a solid oral drug form comprising anti-misuse means and at least one active ingredient, which is characterized in that: at least part of the active ingredient is contained in microparticles; and the anti-misuse means comprise anti-crushing means (a) which enable the microparticles of the active ingredient to resist crushing, such as to prevent the misuse thereof. According to the invention, the drug form can also comprise means (b) for preventing the misuse of the active ingredient following a possible liquid extraction process.

Claims

1. A solid oral drug form comprising anti-misuse means and at least one active ingredient (API), characterized in that at least a part of the API is contained in microparticles, and characterized in that the anti-misuse means comprise anti-crushing means (a) provided so as to allow the microparticles of API to withstand crushing, so as to prevent misuse.

2. The drug form as claimed in claim 1, characterized in that it comprises means (b) provided for preventing misuse of the API after a possible liquid extraction.

3. The drug form as claimed in any one of the preceding claims, characterized in that the anti-crushing means (a) are:

an overcoating for protection of the microparticles of API having at least one of the following characteristics;

a viscoelastic properties for absorbing the energy dissipated during crushing,

a low cohesive strength for promoting breaking of the overcoating and not of the microparticles,

a low surface energy for promoting slipping of the microparticles during crushing,

an ability to form a paste under high shear,

and/or excipients in the free state, i.e. not contained in nor supported by microparticles, and capable of acting against, or even preventing, the crushing of the microparticles of API.

4. The drug form as claimed in any one of the preceding claims, characterized in that at least a part of the microparticles of API are microparticles for modified release of API, preferably microcapsules for modified release of API.

5. The drug form as claimed in claims 3 and 4, characterized in that the overcoating for the protection of the microparticles for modified release of API is designed in such a way that it makes it possible, in the event of crushing, to maintain a non-immediate release for at least a part of said microparticles for modified release of API.

6. The drug form as claimed in claim 3 or 5, characterized in that the overcoating for the protection of the microparticles of API comprises:

(i) at least one film-forming compound which ensures the cohesion of the overcoating, and at least one of the following three compounds;

(ii) a lubricant/caking agent,

(iii) a viscoelastic compound,

(iv) a plasticizer.

7. The drug form as claimed in claim 6, characterized in that the film-forming compound (i) is chosen from:

cellulose derivatives,

acrylic derivatives,

and mixtures thereof.

8. The drug form as claimed in claim 6, characterized in that the lubricant/caking agent (ii) is chosen from the group comprising:

stearic acid and stearates, preferably calcium stearate, zinc stearate or magnesium stearate;

magnesium oxide;

poloxamers;

sodium benzoate;

anionic, cationic or nonionic surfactants;

starches, preferably corn starch;

talc;

colloidal silica;

waxes, preferably hydrogenated plant oils, and even more preferably hydrogenated cottonseed oils, hydrogenated soybean oils, hydrogenated palm oils, hydrogenated castor oils;

glyceryl behenates, tristearins, tripalmitins, trimyristins, yellow waxes, hard fats, anhydrous dairy fats, lanolins, glyceryl palmitostearates, glyceryl stearates, lauric acid macrogol glycerides, cetyl alcohols, glyceryl diisostearates, diethylene glycol monostearates, ethylene monostearates, omegas-3, and mixtures thereof;

fatty bases for suppositories, comprising glycerol, triglycerides, theobroma oils, cocoa butters, and mixtures thereof;

and mixtures thereof.

9. The drug form as claimed in claim 6, characterized in that the viscoelastic agent (iii) is selected from the group of following products:

poly-N-vinylamides,

gum bases,

fatty alcohols,

poly-N-vinyllactams,

polyvinyl alcohols (PVAs),

polyoxyethylenes (POEs),

polyethylene glycols (PEGs),

polydextroses,

hydrogenated mono-, di- and polysaccharides,

polyvinylpyrrolidones (PVPs) (the latter being preferred),

and mixtures thereof.

10. The drug form as claimed in claim 6, characterized in that the plasticizer (iv) is selected from the group of following products:

glycerol and its esters, preferably from the following subgroup;

acetylated glycerides, glyceryl monostearate, glyceryl triacetate, glyceryl tributyrate,

phthalates, preferably from the following subgroup;

dibutyl phthalate, diethyl phthalate, dimethyl phthalate, dioctyl phthalate,

citrates, preferably from the following subgroup;

acetyl tributyl citrate, acetyl triethyl citrate, tributyl citrate, triethyl citrate,

sebacates, preferably from the following subgroup;

diethyl sebacate, dibutyl sebacate,

adipates,

azelates,

benzoates,

plant oils, preferably cottonseed oils, soybean oils, palm oils, castor oils, and mixtures thereof;

fumarates, preferably diethyl fumarate,

malates, preferably diethyl malate,

oxalates, preferably diethyl oxalate,

succinates, preferably dibutyl succinate,

butyrates,

cetyl alcohol esters,

triacetin,

malonates, preferably diethyl malonate,

and mixtures thereof.

11. The drug form as claimed in claim 3, characterized in that the excipients included in the anti-crushing means (a) are chosen from:

compression agents,

and/or inert microbeads,

and/or gum bases,

and/or viscoelastic agents of the type such as those defined above in claim 9.

12. The drug form as claimed in claim 2, characterized in that the means (b) provided for preventing misuse of the API after a possible liquid extraction comprise “

viscosity-modifying”

excipients capable of increasing the viscosity of the extraction liquid so as to act against the misuse, in particular by injection.

13. The drug form as claimed in claim 12, characterized in that the “

viscosity-modifying”

excipients capable of increasing the viscosity of the extraction liquid so as to act against the misuse, in particular by injection, are present;

in and/or on microparticles,

and/or in an overcoating of all or part of the microparticles of API,

and/or in the free state, i.e. not contained in nor carried by microparticles.

14. The drug form as claimed in claim 12 or 13, characterized in that the “

viscosity-modifying”

excipients are capable of increasing the viscosity of the liquid used for the possible extraction according to kinetics similar to the kinetics of extraction of the API contained in the microparticles, so as to trap the extracted API in the viscous medium.

15. The drug form as claimed in any one of claims 12 to 14, characterized in that the excipients included in the means (b) are chosen from the groups of following polymers:

polyacrylic acids and their derivatives, and/or

polyoxyethylenes (POEs), and/or

polyvinyl alcohols (PVAs),

polyvinylpyrrolidones (PVPs), and/or

gelatins, and/or

cellulose derivatives (e.g. hydroxypropylmethylcellulose, methylcellulose, hydroxyethylcellulose, carboxymethylcellulose), and/or

polysaccharides, preferably from the subgroup comprising;

sodium alginate, pectins, guars, xanthans, carragheenans, gellans,

and mixtures thereof.

16. The drug form as claimed in claim 13, characterized in that it comprises means (b) containing “

viscosity-modifying”

excipients, which are in the form of coated particles, each coated with at least one hydrophobic film-coating.

17. The drug form as claimed in any one of the preceding claims, characterized in that it cannot be converted into a dry form which can be administered by nasal aspiration.

18. The drug form as claimed in any one of the preceding claims, characterized in that it cannot be converted into an injectable form.

19. The drug form as claimed in any one of the preceding claims, characterized in that it comprises immediate-release API and/or modified-release API.

20. The drug form as claimed in any one of the preceding claims, characterized in that extraction of the API by chewing and/or crushing is not effective.

21. The drug form as claimed in one of the preceding claims, characterized in that the API used belongs to at least one of the following families of active substances:

amphetamines, analgesics, anorexigens, antalgics, antidepressants, antiepileptics, anti-migraine agents, antiparkinsonian agents, antitussives, anxiolytics, barbiturates, benzodiazepines, hypnotics, laxatives, neuroleptics, opiates, psychostimulants, psychotropic agents, sedatives and stimulants.

22. The drug form as claimed in one of the preceding claims, characterized in that the API used is chosen from the following compounds:

acetorphine, acetylalphamethylfentanyl, acetyldihydrocodeine, acetylmethadol, alfentanil, allylprodine, alphacetylmethadol, alphameprodine, alphamethadol, alphamethylfentanyl, alpha-methylthofentanyl, alphaprodine, anileridine, atropine, benzethidine, benzylmorphine, beta-hydroxyfentanyl, beta-hydroxymethyl-3-fentanyl, beta-cetylmethadol, betameprodine, betamethadol, betaprodine, bezitramide, buprenorphine, dioxaphetyl butyrate, cannabis, cetobemidone, clonitazene, codeine, coca, cocaine, codoxime, concentrate of poppy straw, desomorphine, dextromoramide, dextropropoxyphene, diampromide, diethylthiambutene, difenoxine, dihydrocodeine, dihydroetorphine, dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, diphenoxylate, dipipanone, drotebanol, ecgonin, ephedrine, ethylmethylthiambutene, ethylmorphine, etonitazene, etorphine, etoxeridine, fentanyl, furethidine, heroin, hydrocodone, hydromorphinol, hydromorphone, hydroxypethidine, isomethadone, levomethorphan, levomoramide, levophenacylmorphan, levorphanol, meperidine, metazocine, methadone, methyldesorphine, methyldihydromorphine, methylphenidate, methyl-3-thiofentanyl, methyl-3-fentanyl, metopon, moramide, morpheridine, morphine, MPPP, myrophine, nicocodine, nicodicodine, nicomorphine, noracymethadol, norcodeine, norlevorphanol, normethadone, normorphine, norpipanone, opium, oxycodone, oxymorphone, para-fluorofentanyl, PEPAP, pentazocine, pethidine, phenampromide, phenazocine, phenomorphan, phenoperidine, pholcodine, piminodine, piritramide, proheptazine, propanolol, properidine, propiram, racemethorphan, racemoramide, racemorphan, remifentanil, sufentanil, thebacone, thebaine, thiofentanyl, tilidine, trimeperidine, and mixtures thereof.

23. The drug form as claimed in any one of the preceding claims, characterized in that the microparticles of API have an average diameter of less than or equal to 1000 μ

m, preferably between 50 and 800 microns, and more preferably between 100 and 600 microns.

24. The oral drug form as claimed in any one of the preceding claims, comprising anti-misuse means and a plurality of microcapsules for modified release of at least one analgesic active ingredient (APIa), at least a part of said microcapsules consisting individually of a nucleus comprising at least one APIa and coated with at least one coating for the modified release of the APIa;

the average diameter of said microcapsules being less than or equal to 1000 μ

m, preferably between 50 and 800 μ

m, more preferably between 50 and 600 μ

m, and even more preferably between 80 and 400 μ

m;

characterized;

in that it comprises at least 1000 microcapsules per dose;

and in that the amount of APIa and the modified-release coating are such that they allow an administration once or twice a day for analgesic purposes.

25. The drug form as claimed in claim 24, characterized in that it makes it possible to obtain, after taking one dose, a plasma profile defined as follows:

Cmax/C18h≦

Cmax*/C18h* preferably 1.5×

Cmax/C18h≦

Cmax*/C18h* and even more preferably 2.0×

Cmax/C18h≦

Cmax*/C18h* with

—

C18h representing the plasma concentration of APIa, 18h after taking the dose,

C18h* representing the plasma concentration of APIa obtained under the same conditions as C18h, with a reference immediate-release oral pharmaceutical form, containing the same dose of APIa,

Cmax representing the maximum plasma concentration of APIa after taking the dose,

Cmax* representing the maximum plasma concentration of APIa obtained under the same conditions as Cmax, with a reference immediate-release oral pharmaceutical form, containing the same dose of APIa.

26. The drug form as claimed in claim 24 or 25, characterized in that it results in a decrease in the inter- and/or intraindividual standard deviation of the Cmax, when it is administered orally to a sample of individuals, whatever the fed state or fasting state of the individuals, compared with a pharmaceutical form for immediate release of APIa administered to this same sample of individuals, at the same dose, which makes it possible to ensure a smaller variability in effectiveness and in therapeutic safety of the pharmaceutical form.

27. The drug form as claimed in claim 26, characterized in that the factor (f) of decrease in the interindividual standard deviation of the Cmaxis defined as follows:

f≧

1.05;

preferably, f≧

1.5, and even more preferably, f is between 2.0 and 20.

28. The drug form as claimed in any one of claims 24 to 27, characterized in that it results, when it is administered orally to a sample of individuals, in a mean peak/trough modulation of the plasma profiles of the APIa less than or equal to the mean peak/trough modulation of the APIa of the same sample of individuals having received the same dose of a form for immediate release of APIa;

preferably, the peak/trough modulation decrease factor g is such that;

g≧

1.05;

preferably, g≧

1.5, and even more preferably, g is between 2.5 and 20.

29. The drug form as claimed in claim 24 or 25, characterized in that it comprises microgranules for immediate release of APIa.

30. The drug form as claimed in any one of claims 24 to 29, characterized in that 70% of the APIa is released in vitro between 1 and 24 h, preferably 2 and 15 h, and more preferably 2 and 12 h.

31. The drug form as claimed in claim 30, characterized by an in vitro dissolution profile of the oral pharmaceutical form such that, for any value of the time t of between 2 h and t(70%), preferably for any value of time t of between 1 h and t(70%), the percentage of APIa dissolved is greater than or equal to 35 t/t(70%).

32. The drug form as claimed in any one of claims 24 to 29, characterized in that:

the release of the APIa is controlled by two distinct triggering mechanisms, one being based on a variation in pH and the other allowing the release of the APIa after a predetermined residence time in the stomach;

at constant pH 1.4, the dissolution profile contains a lag phase which lasts less than or equal to 7 hours, preferably less than or equal to 5 hours, and even more preferably between 1 and 5 hours,

and the passing from pH 1.4 to pH 7.0 results in a release phase which begins without any lag time.

33. The drug form as claimed in any one of claims 24 to 32, characterized in that it comprises at least two populations of microcapsules having different release profiles according to the similarity factor f2 test.

34. The drug form as claimed in any one of claims 24 to 33, characterized in that it is in the form of a single oral daily dose comprising from 1000 to 500 000 microunits containing APIa.

35. The drug form as claimed in any one of claims 24 to 34, characterized in that it is in the form of a single oral daily dose comprising from 1000 to 500 000 microcapsules for modified release of APIa.

36. The drug form as claimed in any one of claims 24 to 35, characterized in that it comprises at least one active ingredient (API) other than the APIa.

37. The drug form as claimed in any one of claims 24 to 36, characterized in that it comprises at least one suspension of microcapsules of APIa in an aqueous liquid phase which is preferably saturated or which becomes saturated with APIa on contact with the microcapsules, the coating of said microcapsules preferably having a composition corresponding to one of the following two families A′

and B′

;

family A′

1A′

—

at least one film-forming polymer (P1) which is insoluble in the fluids of the tract, present in a proportion of 50% to 90%, preferably 50% to 80% by weight on a dry basis relative to the total mass of the coating composition, and comprising at least one water-insoluble derivative of cellulose;

2A′

—

at least one nitrogenous polymer (P2) present in a proportion of 2% to 25%, preferably 5% to 15% by weight on a dry basis relative to the total mass of the coating composition and consisting of at least one polyacrylamide and/or one poly-N-vinylamide and/or one poly-N-vinyllactam;

3A′

—

at least one plasticizer present in a proportion of 2% to 20%, preferably of 4% to 15% by weight on a dry basis relative to the total mass of the coating composition and consisting of at least one of the following compounds;

glyceryl esters, phthalates, citrates, sebacates, cetyl alcohol esters, castor oil;

4A′

—

at least one surfactant and/or lubricant, present in a proportion of 2% to 20%, preferably of 4% to 15% by weight on a dry basis relative to the total mass of the coating composition and chosen from anionic surfactants and/or from nonionic surfactants and/or from lubricants;

it being possible for said surfactant and/or lubricant to comprise just one or a mixture of the abovementioned products;

family B′

1B′

—

at least one film-forming polymer which is insoluble in the fluids of the gastrointestinal tract,

2B′

—

at least one water-soluble polymer,

3B′

—

at least one plasticizer,

4B′

—

and, optionally, at least one surfactant/lubricant, preferably selected from the group of following products;

anionic surfactants,

and/or nonionic surfactants.

38. The drug form as claimed in any one of claims 24 to 37, characterized in that it comprises at least one powder for oral suspension to be reconstituted, of microcapsules of APIa, to which the user must add the water or the liquid phase in order to reconstitute the suspension.

39. The drug form as claimed in any one of the preceding claims, characterized in that it is in the form of a sachet of microcapsule powder, of a tablet obtained from microcapsules, or of a gel capsule containing microcapsules.

40. The drug form as claimed in any one of the preceding claims, characterized in that it is free of antagonist(s) of the API or of the APIa.

41. The use of the microcapsules for modified release of APIa as defined in claim 24, and optionally of the microgranules for immediate release of APIa as defined in claim 29, for the preparation of pharmaceutical, microparticulate oral galenic forms, preferably in the form of tablets, advantageously orodispersible tablets, of powders, of gel capsules or of suspensions.

42. The use of the microcapsules for modified release of APIa as defined in claim 24, and optionally of the microgranules for immediate release of APIa as defined in claim 29, for the preparation of a therapeutically safe, microparticulate oral pharmaceutical form designed in such a way that, once said pharmaceutical form has been ingested, the microcapsules that it contains are dispersed and individualized when they reach the stomach, which allows these microcapsules to be subjected to regular and gradual gastric emptying, whether the patient had eaten or was fasting at the time the dose was taken, thus guaranteeing a release of APIa within its gastrointestinal window of bioabsorption.